Sales 9% below us, but partly temporary; orders grew 61% Mixed outlook, reiterates guidance, but cit...
Redeye provides an update following Truecaller’s Q1 2025 report, which came in softer than expected.
Redeye noted that BeammWave's Q1 2025 report significantly exceeded expectations, primarily due to r...
Redeye notes that Sivers’ Q1 2025 report was strong, with another quarter of record net sales reachi...
Redeye comments on Active Biotech’s Q1 report 2025.
Redeye retains its Base Case and makes minor forecast adjustments following the full Q1 report, with...
Strong Q1 sales of SEK 57m, +49% y-o-y '25e-'27e sales and EBIT up 5-6% and 9%, respectively Growth ...
Redeye embraces the news of AroCell’s expanded cooperation with Concile to reach markets outside Ger...
AcuCort (”AcuCort” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första kvartalet 2...
Redeye provides an initial take following the release of Corline’s Q1 2025 report.
Kontraktstillverkaren Hanza levererade för tredje kvartalet i rad en stark rapport med förbättrade m...
Redeye notes that Paxman completes the offer to Dignitana.
Redeye states that the Q1 report came in above our estimates on both sales and adjusted EBITDA, with...
Redeye comments on Tessin’s Q1 results, which came in much weaker than expected.
Sales 2% higher than expected; 24% y-o-y FX adjusted But higher investments increased lead to miss o...
